<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02307916</url>
  </required_header>
  <id_info>
    <org_study_id>16-043</org_study_id>
    <nct_id>NCT02307916</nct_id>
  </id_info>
  <brief_title>Fibroblast Growth Factor Regeneration of Tympanic Membrane Perforations</brief_title>
  <official_title>Fibroblast Growth Factor Regeneration of Tympanic Membrane Perforations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Bradley Welling</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts Eye and Ear Infirmary</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase II randomized trial will be initiated to evaluate closure of the perforated tympanic
      membrane as the primary measureable outcome. The goal is to determine the safety and efficacy
      of Fibroblast Growth Factor-2 (FGF-2) in the closure of chronic tympanic membrane
      perforations (TMP). If FGF-2 is topically applied for the treatment of chronic TMP in humans,
      it is hypothesized it will be safe, tolerable and effective for use as treatment for tympanic
      membrane perforation. A total of 60 subjects will be recruited.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase II randomized trial will be initiated to evaluate efficacy as the primary measureable
      outcome. Eligible and consented patients will be randomized in a 3:1 ratio to the optimal
      biologic dose (OBD) of FGF-2 or placebo (sterile water).

      Application of the study treatment may occur at the initial Screening Visit (pending all
      eligibility requirements can be confirmed) or at Visit 1 and may be repeated at each follow
      up visit as needed for a maximum of three treatments per treatment arm. These follow up
      visits will occur three weeks (+/- 7 days) from the last treatment application. During these
      visits, the subject's tympanic membrane will be examined, photographed, and additional
      otologic tests will be performed. If the perforation is found to be closed during these
      visits, then the subject will report in 2 months (+/-7 days) for a final study visit.

      If the subject's TMP has not closed after the third and final application of their assigned
      treatment group, then the subject will be crossed over to the other treatment group. Again,
      the subject may be given up to three additional treatments in this new group. The follow up
      visits will follow the same schedule, occurring three weeks (+/- 7 days) from the last
      treatment. The same otologic procedures will be performed as in the previous visits.

      All subjects will report for a final study visit 2 months (+/- 7 days) after their last
      follow up visit when the perforation is determined to be closed or when the subject has
      completed the maximum number of study visits without perforation closure. The study will be
      completed for reporting purposes after all subjects have completed the 2 month (+/- 7 days)
      follow up final visit.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Actual">July 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Tympanic Membrane Closure Following Treatment</measure>
    <time_frame>~60 days</time_frame>
    <description>The efficacy of the treatment is determined by the number of patients whose tympanic membrane perforations closed after study treatments. Subjects from both treatment arms received up to three treatments before determining non-closure of the tympanic membrane.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of Changes in Pure-tone Averages</measure>
    <time_frame>Baseline, 60 days</time_frame>
    <description>measured by pre- and post-treatment audiograms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Changes in Speech Discrimination Scores</measure>
    <time_frame>Baseline, 60 days</time_frame>
    <description>Speech discrimination score is determined by having the patient listen to words through headphones and having the patient repeat the words back to the audiologist. A score of 100 percent (100%) is the best outcome, and 0 percent (0%) is the worst. Pre- and post- treatment tests are compared and analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Treatments Required for Closure of the Tympanic Membrane Perforation</measure>
    <time_frame>60 days</time_frame>
    <description>Out of the patients who healed, some healed with 1 treatment, some with 2 treatments, and some with 3 treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Normal Mobility of the Eardrum as Assessed by Tympanometry</measure>
    <time_frame>60 days</time_frame>
    <description>Tympanometry is an examination used to test the condition of the middle ear and the mobility of the eardrum. Any type of perforation, regardless of size, would cause the result of the tympanometry to be abnormal. We use this test to determine if the eardrum closed completely.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Tympanic Membrane Perforation</condition>
  <arm_group>
    <arm_group_label>FGF-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FGF-2 given a minimum of 1 and maximum of 3 times within, approximately, 60 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Equal concentration of saline is given a minimum of 1 and maximum of 3 times within, approximately, 60 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FGF-2</intervention_name>
    <description>The FGF-2 method of use comprises a pledget of gelatin foam with human fibroblast growth factor-2 (FGF-2) added to the pledget just before topical application to the tympanic membrane, and the use of Tisseel, a fibrin glue used for applications in ear surgery.</description>
    <arm_group_label>FGF-2</arm_group_label>
    <other_name>FGF2, Human Fibroblast Growth Factor 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator using a sterile saline solution.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo comparator; sterile saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Dry tympanic membrane perforation of greater than 3 months duration

          2. If female, post-menopausal or sterile, or if she is of child-bearing potential, must
             have a negative beta-human chorionic gonadotropin (HCG) test and must be using an
             adequate form of birth control such as birth control pills, birth control implants,
             intrauterine devices (IUDs), diaphragms or condoms.

        Exclusion Criteria:

        The presence of any of the following excludes a subject from study enrollment:

          -  Active otitis media or chronic otorrhea from the middle ear

          -  Subjects receiving radiation therapy, corticosteroids, immunosuppressive agents or
             chemotherapy

          -  Subjects who, at study entry, are taking systemic antibiotics

          -  Subjects who are immunosuppressed

          -  Subjects experiencing bacterial or viral infection or who may otherwise be febrile

          -  Life expectancy of less than 1 year

          -  Active alcohol or drug abuse within 6 months prior to study entry

          -  Significant medical condition that could prevent full participation in the procedures
             required for the study (See body of protocol for full list of exclusions)

          -  Known or suspected allergies to any components used in the study

          -  Subjects who have cholesteatoma mass in the tympanic cavity

          -  Subjects whose total perforation cannot be seen by an endoscope

          -  Subjects with inadequately controlled diabetes mellitus (NGSP: HbA1c 6.9% or higher)

          -  Subjects with a history of malignant ear canal tumors within 3 years of screening for
             eligibility
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>D. B. Welling, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts Eye and Ear</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilford Hall, Lackland Airforce Base</name>
      <address>
        <city>Lackland Air Force Base</city>
        <state>Texas</state>
        <zip>78236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 2, 2014</study_first_submitted>
  <study_first_submitted_qc>December 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2014</study_first_posted>
  <results_first_submitted>April 22, 2020</results_first_submitted>
  <results_first_submitted_qc>June 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 11, 2020</results_first_posted>
  <last_update_submitted>June 1, 2020</last_update_submitted>
  <last_update_submitted_qc>June 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts Eye and Ear Infirmary</investigator_affiliation>
    <investigator_full_name>Dr. Bradley Welling</investigator_full_name>
    <investigator_title>Principal Investigator, M.D., Ph.D.</investigator_title>
  </responsible_party>
  <keyword>tympanic membrane perforation</keyword>
  <keyword>ear drum</keyword>
  <keyword>hole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tympanic Membrane Perforation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT02307916/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Patients who met exclusion criteria were considered &quot;screen-fail&quot; and were not assigned to a randomization group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>FGF-2</title>
          <description>FGF-2 given a minimum of 1 and maximum of 3 times within, approximately, 60 days.
FGF-2: The FGF-2 method of use comprises a pledget of gelatin foam with human fibroblast growth factor-2 (FGF-2) added to the pledget just before topical application to the tympanic membrane, and the use of Tisseel, a fibrin glue used for applications in ear surgery.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Equal concentration of saline is given a minimum of 1 and maximum of 3 times within, approximately, 60 days.
Placebo: Placebo comparator using a sterile saline solution.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FGF-2</title>
          <description>FGF-2 given a minimum of 1 and maximum of 3 times within, approximately, 60 days.
FGF-2: The FGF-2 method of use comprises a pledget of gelatin foam with human fibroblast growth factor-2 (FGF-2) added to the pledget just before topical application to the tympanic membrane, and the use of Tisseel, a fibrin glue used for applications in ear surgery.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Equal concentration of saline is given a minimum of 1 and maximum of 3 times within, approximately, 60 days.
Placebo: Placebo comparator using a sterile saline solution.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="57"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="42"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="42"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.7" spread="13.9"/>
                    <measurement group_id="B2" value="55.8" spread="15"/>
                    <measurement group_id="B3" value="52.7" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="42"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="42"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Tympanic Membrane Closure Following Treatment</title>
        <description>The efficacy of the treatment is determined by the number of patients whose tympanic membrane perforations closed after study treatments. Subjects from both treatment arms received up to three treatments before determining non-closure of the tympanic membrane.</description>
        <time_frame>~60 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FGF-2</title>
            <description>FGF-2 given a minimum of 1 and maximum of 3 times within, approximately, 60 days.
FGF-2: The FGF-2 method of use comprises a pledget of gelatin foam with human fibroblast growth factor-2 (FGF-2) added to the pledget just before topical application to the tympanic membrane, and the use of Tisseel, a fibrin glue used for applications in ear surgery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Equal concentration of saline is given a minimum of 1 and maximum of 3 times within, approximately, 60 days.
Placebo: Placebo comparator using a sterile saline solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Tympanic Membrane Closure Following Treatment</title>
          <description>The efficacy of the treatment is determined by the number of patients whose tympanic membrane perforations closed after study treatments. Subjects from both treatment arms received up to three treatments before determining non-closure of the tympanic membrane.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of Changes in Pure-tone Averages</title>
        <description>measured by pre- and post-treatment audiograms.</description>
        <time_frame>Baseline, 60 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FGF-2</title>
            <description>FGF-2 given a minimum of 1 and maximum of 3 times within, approximately, 60 days.
FGF-2: The FGF-2 method of use comprises a pledget of gelatin foam with human fibroblast growth factor-2 (FGF-2) added to the pledget just before topical application to the tympanic membrane, and the use of Tisseel, a fibrin glue used for applications in ear surgery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Equal concentration of saline is given a minimum of 1 and maximum of 3 times within, approximately, 60 days.
Placebo: Placebo comparator using a sterile saline solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Changes in Pure-tone Averages</title>
          <description>measured by pre- and post-treatment audiograms.</description>
          <units>dB</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="8.8"/>
                    <measurement group_id="O2" value="5.9" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of Changes in Speech Discrimination Scores</title>
        <description>Speech discrimination score is determined by having the patient listen to words through headphones and having the patient repeat the words back to the audiologist. A score of 100 percent (100%) is the best outcome, and 0 percent (0%) is the worst. Pre- and post- treatment tests are compared and analyzed.</description>
        <time_frame>Baseline, 60 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FGF-2</title>
            <description>FGF-2 given a minimum of 1 and maximum of 3 times within, approximately, 60 days.
FGF-2: The FGF-2 method of use comprises a pledget of gelatin foam with human fibroblast growth factor-2 (FGF-2) added to the pledget just before topical application to the tympanic membrane, and the use of Tisseel, a fibrin glue used for applications in ear surgery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Equal concentration of saline is given a minimum of 1 and maximum of 3 times within, approximately, 60 days.
Placebo: Placebo comparator using a sterile saline solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Changes in Speech Discrimination Scores</title>
          <description>Speech discrimination score is determined by having the patient listen to words through headphones and having the patient repeat the words back to the audiologist. A score of 100 percent (100%) is the best outcome, and 0 percent (0%) is the worst. Pre- and post- treatment tests are compared and analyzed.</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="8.1"/>
                    <measurement group_id="O2" value="1.7" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Treatments Required for Closure of the Tympanic Membrane Perforation</title>
        <description>Out of the patients who healed, some healed with 1 treatment, some with 2 treatments, and some with 3 treatments.</description>
        <time_frame>60 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FGF-2</title>
            <description>FGF-2 given a minimum of 1 and maximum of 3 times within, approximately, 60 days.
FGF-2: The FGF-2 method of use comprises a pledget of gelatin foam with human fibroblast growth factor-2 (FGF-2) added to the pledget just before topical application to the tympanic membrane, and the use of Tisseel, a fibrin glue used for applications in ear surgery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Equal concentration of saline is given a minimum of 1 and maximum of 3 times within, approximately, 60 days.
Placebo: Placebo comparator using a sterile saline solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Treatments Required for Closure of the Tympanic Membrane Perforation</title>
          <description>Out of the patients who healed, some healed with 1 treatment, some with 2 treatments, and some with 3 treatments.</description>
          <units>treatments</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.6"/>
                    <measurement group_id="O2" value="1.7" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Normal Mobility of the Eardrum as Assessed by Tympanometry</title>
        <description>Tympanometry is an examination used to test the condition of the middle ear and the mobility of the eardrum. Any type of perforation, regardless of size, would cause the result of the tympanometry to be abnormal. We use this test to determine if the eardrum closed completely.</description>
        <time_frame>60 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FGF-2</title>
            <description>FGF-2 given a minimum of 1 and maximum of 3 times within, approximately, 60 days.
FGF-2: The FGF-2 method of use comprises a pledget of gelatin foam with human fibroblast growth factor-2 (FGF-2) added to the pledget just before topical application to the tympanic membrane, and the use of Tisseel, a fibrin glue used for applications in ear surgery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Equal concentration of saline is given a minimum of 1 and maximum of 3 times within, approximately, 60 days.
Placebo: Placebo comparator using a sterile saline solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Normal Mobility of the Eardrum as Assessed by Tympanometry</title>
          <description>Tympanometry is an examination used to test the condition of the middle ear and the mobility of the eardrum. Any type of perforation, regardless of size, would cause the result of the tympanometry to be abnormal. We use this test to determine if the eardrum closed completely.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from the time of enrollment to the final follow-up visit, usually within 6 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>FGF-2</title>
          <description>FGF-2 given a minimum of 1 and maximum of 3 times within, approximately, 60 days.
FGF-2: The FGF-2 method of use comprises a pledget of gelatin foam with human fibroblast growth factor-2 (FGF-2) added to the pledget just before topical application to the tympanic membrane, and the use of Tisseel, a fibrin glue used for applications in ear surgery.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Equal concentration of saline is given a minimum of 1 and maximum of 3 times within, approximately, 60 days.
Placebo: Placebo comparator using a sterile saline solution.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear drainage post-treatment</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Ear pain during procedure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Brad Welling</name_or_title>
      <organization>Massachusetts Eye and Ear</organization>
      <phone>617-573-4075</phone>
      <email>brad_welling@meei.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

